Henry Smith: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 March 2022 to Question 141960 on Evusheld, what progress has been made on the assessment of Evusheld for treating immunocompromised patients.
Caroline Lucas: To ask the Secretary of State for Health and Social Care, what research the Government is commissioning to assess the efficacy of Evusheld against covid-19 variants; when data from that research will be available; and if he will make a statement.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, if he will commit to making (a) Evusheld and (b) other preventative treatments available via the NHS for prophylactic use for people who are at high risk of severe illness from covid-19 as soon as possible.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, for what reason the Government is conducting tests of the drug, Evusheld, on covid-19 omicron subvariants in the context of the United States Food and Drug Administration and the European Medicines Agency having demonstrated through similar studies that that drug maintains protection.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, whether he plans to place an order for the drug, Evusheld.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the timeframe for Evusheld being available for eligible patients following its recent MHRA approval.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, whether the Government has undertaken an assessment of which immunocompromised patients should be eligible for treatment with the drug, Evusheld, due to their lack of response to the covid-19 vaccine; and whether the Government has plans to undertake antibody testing on those individuals to assess their response.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, when the results of Government’s tests on the effectiveness of the the drug evusheld against covid-19 omicron subvariants will be published.
Lord Mendelsohn: To ask Her Majesty's Government whether, other than Evusheld, they are aware of any monoclonal antibody treatment that can protect the clinically extremely vulnerable through pre-exposure prophylaxis (PREP) against Omicron and its variants; and, if so, to list them.
Henry Smith: ...and Social Care, in the context of the Conditional Marketing Authorisation awarded by the Medicines and Healthcare products Regulatory Agencyon 17 March 2022, what plans he has to (a) procure Evusheld and (b) roll out the treatment to severely immunocompromised patients.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, what plans his Department has to rollout Evusheld to immunocompromised and immunosuppressed patients.
Duncan Baker: ...Marketing Authorisation awarded by the Medicines and Healthcare products Regulatory Agency on 17 March 2022, what plans he has to ensure that severely immunocompromised patients have access to Evusheld; and what estimate he has made of when the first patients will start to receive that treatment.
Andrew Gwynne: To ask the Secretary of State for Health and Social Care, what his timeframe is for reaching an agreement with relevant companies on the purchase of doses of the covid-19 antibody drug, Evusheld.
Hilary Benn: To ask the Secretary of State for Health and Social Care, if the NHS will make available Evusheld as a preventative covid-19 treatment for people who are immunosuppressed.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, what discussions he has had with the MHRA on approving the antibody treatment Evusheld.
Lord Lansley: To ask Her Majesty's Government what assessment they have made of the emergency use authorisation listed on 8 December 2021 of AstraZeneca's Evusheld for pre-exposure prophylaxis in (1) certain adults, and (2) children.
Daisy Cooper: To ask the Secretary of State for Health and Social Care, whether the UK intends to place an order of Evusheld in advance of its potential approval by the MHRA.
Amy Callaghan: To ask the Secretary of State for Health and Social Care, whether his Department has plans to procure and roll out (a) AstraZeneca's Evusheld and (b) other preventative treatments, for those in the clinically extremely vulnerable group and immunosuppressed people, as remaining covid-19 restrictions are lifted.
Lord Mendelsohn: To ask Her Majesty's Government how much Evusheld monoclonal antibody treatment they have secured; and when this treatment will be available to the clinically vulnerable in the UK.
Duncan Baker: To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the AstraZeneca drug Evusheld for immunosuppressed people in the UK; what plans he has to use that drug as a (a) prophylactic and (b) treatment; and what his timeline is for the rollout of that drug for use in the UK.